8-K ·Filed Apr 22, 2026
8-K context-dependent: Items 7.01
Actionable Insight ▲ Bullish
Monitor for upcoming data from the registrational Phase 2b SAFEGUARD trial expected in 2H 2027, as this will be more definitive for the therapy's efficacy.
Final — all horizons settled through T+60d
SABSW ▼ -54.75% at T+60d
LONG call ✗ call lost -54.75% · α vs SPY -59.53% · entry $0.0358 → $0.0162
T+1d
0.00%
call 0.00% · α +0.39%
$0.0358
settled 6mo ago
T+5d
-55.31%
call -55.31% · α -55.36%
$0.0160
settled 6mo ago
T+20d
0.00%
call 0.00% · α -3.17%
$0.0358
settled 5mo ago
T+60d
-54.75%
call -54.75% · α -59.53%
$0.0162
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
SAB Biotherapeutics presented positive Phase 1 clinical data for its SAB-142 therapy in Type 1 Diabetes patients, showing C-peptide preservation and improved glycemic control. The data was presented at the Immunology of Diabetes Society Congress.
Key Facts
- All 4 T1D participants receiving SAB-142 showed C-peptide preservation
- 3 of 4 participants showed a 'super responder' profile
- T1D participants showed improved glycemic control with mean Time in Range increasing from 73% at baseline to 85% at Day 120
- Data presented at the 21st Immunology of Diabetes Society (IDS) Congress in Brisbane, Australia
- SAB-142 is a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes
Financial Impact
Positive clinical data for SAB-142 in Phase 1 trial, but no financial figures disclosed
clinical trial resultsdrug development progress
Risk Factors
- Phase 1 data is preliminary and from a small cohort of only 4 patients
- The stock has a very low market cap of $1M, indicating high risk
- The company is still in clinical-stage development with no approved products
Market Snapshot
Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-168569 |
| Document: sabs-ex99_1.htm | 0001193125-26-168569 |
| Document: 0001193125-26-168569-index-headers.html | 0001193125-26-168569 |
| Document: 0001193125-26-168569-index.html | 0001193125-26-168569 |
| Document: 0001193125-26-168569.txt | 0001193125-26-168569 |
2 reports for SABSW
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
May 4, 2026 25w ago | 8-K | $0.0358 $0.0140 | ▼ −60.89% | ▼ −63.63% | — |
Apr 22, 2026 26w ago | 8-K | $0.0358 $0.0162 | ▼ −54.75% | ▼ −59.53% | — |
Showing 2 of 2
US Market Status
Market Closed — Opens Thu (12h 53m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers